Skip to main content

2014 - James E. Bradner

A Case for Open-Source Drug Discovery

James E. Bradner, MD is a Staff Physician in the Division of Hematologic Malignancies at Dana-Farber Cancer Institute as well as an Associate Professor in Medicine at Harvard Medical School. The present research focus of the Bradner laboratory concerns the discovery and optimization of prototype drugs targeting cancer gene regulation. The clinical objective of the Bradner group is to deliver novel therapeutics for human clinical investigation in hematologic diseases. 

Dr. Bradner’s awards and honors include the Damon Runyon-Rachleff Innovation Award, the Smith Family Award for Excellence in Biomedical Research, the Dunkin Donuts Rising Star Award and the HMS Distinguished Excellence in Teaching Award. He is a member of the American Society of Hematology, the American Chemical Society and the American Society of Clinical Investigation. His recent research has been published in Nature, Cell, Nature Chemical Biology and the Journal of the American Chemical Society. He has authored more than twenty-five United States Patent applications and is a scientific founder of Acetylon Pharmaceuticals, SHAPE Pharmaceuticals, Tensha Therapeutics and Syros Pharmaceuticals. 

 Dr. Bradner received his AB from Harvard University, his MD from the University of Chicago, and an MMS from Harvard Medical School. He completed his postgraduate training in Internal Medicine at Brigham & Women's Hospital, followed by fellowships in Medical Oncology and Hematology at Dana-Farber Cancer Institute. Following additional post-doctoral training in Chemistry with Prof. Stuart Schreiber at Harvard University and the Broad Institute, Dr. Bradner joined the research faculty of Dana-Farber in 2008.